Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosed with hematological diseases.~2. recipients of allogeneic peripheral blood stem cell transplantation.~3. new onset of grade II\~IV acute graft versus host disease within 100 days post-transplantation.~exclusion criteria:~1. recipients of second allogeneic stem cell transplant.~2. acute GVHD induced by donor lymphocyte infusion, interferon.~3. received treatment other than steroid before enrollment.~4. overlap GVHD syndrome.~5. pregnant or breast-feeding women.~6. absolute neutrophil count (ANC) \<0.5×10e9/L or platelet count (PLT) \< 20×10e9/L~7. non-GVHD related liver dysfunction: glutamic pyruvic transaminase\>= 4 times of upper normal limit, direct bilirubin \>= 4 times of upper normal limit~8. renal dysfunction: creatinine clearance \< 15 mL/min or glomerular filtration rate\< 15 mL/min~9. uncontrolled infection~10. human immunodeficiency virus infection~11. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.~12. relapse of primary malignant hematological diseases, or graft rejection.~13. allergic history to Janus kinase inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- combination therapy (Type: EXPERIMENTAL): There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~1. Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~2. Ruxolitinib oral tablet, 5\~10mg bid orally, for at least 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).